+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Innovations in Liquid Biopsy Techniques for Cancer Management

  • ID: 4392216
  • Report
  • August 2017
  • Region: Global
  • 66 pages
  • Frost & Sullivan
Liquid Biopsy Technologies Likely to Lead the Transformation of Cancer Profiling and Personalized Treatment Strategies

This research service encompasses a comprehensive analysis of minimally-invasive and non-invasive biopsy platforms that enable enhanced tumor profiling, treatment monitoring and precision oncology applications. This service primarily focuses on the use of circulating tumor DNA (ctDNA) circulating tumor cells (CTCs) and extracellular vesicles (EVs), derived from bio-fluids such as blood and urine, for molecular analysis across research and healthcare settings. This study also evaluates the technology, clinical, patent, and application landscapes prevalent across liquid biopsy settings, while providing valuable insights across its global technological impact and future perspectives.

Note: Product cover images may vary from those shown

1.0 Executive Summary

1.0 Executive Summary
1.1 Research Scope
1.2 Research Methodology
1.3 Key Findings

2.0 Technology Snapshot and Overview
2.1 Overview of Key Liquid Biopsy (LB) Markers
2.2 Key Liquid Biopsy Markers Comprise Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and Extracellular Vesicles (EVs)

3.0 Technologies Analyzing ctDNA
3.1 Next-Generation Sequencing Platforms Likely to Fuel ctDNA Analysis
3.2 Overview of PCR-Based Technologies for ctDNA Analysis
3.3 Next-Generation Sequencing Tools for ctDNA Assessment
3.4 Emerging ctDNA Technologies Likely to Enable Comprehensive genome Profiling
3.5 ctDNA Leads Profiling and Therapy Monitoring Applications in Clinical Trial Studies
3.6 China Leads the Global Patent Landscape for ctDNA-based Technologies
3.7 Research Funding in US for ctDNA-based Projects Exceed $50M in 2015-2016 Period
3.8 ctDNA Biomarkers Studies Likely to Accelerate Disease and Treatment Profiling Applications
3.9 Leveraging Epigenetic Tools across Cancer Diagnostics
3.10 Enabling Personalized Management of Cancer

4.0 Technologies Enabling CTC Detection
4.1 Circulating Tumor Cells Enable Comprehensive Analysis of Cancer
4.2 Cellular Analytics for CTCs Enable Prognostic Insights for Cancer
4.3 Technologies Facilitating Molecular Analysis of CTCs Likely to Transform Cancer Management
4.4 Emerging Use of Microfluidic and Imaging Technologies Enhance CTC Analysis
4.5 China Leads the Global Patent Landscape for CTCs
4.6 NIH funding for CTC-based Projects Exceeded $150 million during 2015-2016
4.7 CTCs Likely to Lead Disease Profiling, Treatment Profiling and Prognostic Applications across Several Cancers
4.8 Combining ctDNA and CTC Analyses for Liquid Biopsy Assays
4.9 US FDA Approved CTC Assay

5.0 Technologies for Assessment of Extracellular Vesicles
5.1 Exosomes Likely to Garner Growing Attention across Cancer Liquid Biopsy Applications
5.2 Affinity Capture and Microfluidics techniques Likely to Enhance Exosome Isolation and Detection in the Near Future
5.3 Advances across Proteomic and Nucleic Acid Assay Techniques Likely to Enhance Exosome Markers Detection
5.4 North America Leads the Global Patent Landscape for Extracellular Vesicle-based Technologies
5.5 US Research Funding for EV-based Technologies Exceeds $250 Million during 2015-2016
5.6 Exosomal Markers Likely to Lead Disease Profiling and Treatment Monitoring Applications
5.7 Exosome-based Liquid Biopsy Assays for Precision Oncology
5.8 Novel Platforms for Enhanced Isolation of EVs

6.0 Impact Analysis and Future Perspectives
6.1 Summary of Key Technology Drivers
6.2 Technology Advancements and Rising Preference for Minimally Invasive Methods Likely to Fuel Liquid Biopsy Platforms
6.3 Summary of Key Technology Challenges
6.4 Enhancing Assay Accuracy and Clinical Utility of Biomarkers Constitute Key Challenges across Liquid Biopsy Tests
6.5 Liquid Biopsy Platforms Likely to Transform Disease Profiling and Precision Medicine Applications

7.0 Growth Opportunities and Companies to Action
7.1 Growth Opportunity 1: ctDNA
7.2 Growth Opportunity 2: CTCs
7.3 Growth Opportunity 3: EVs
7.4 Strategic Imperatives for Success and Growth

8.0 Appendix
8.1 Key Contacts
Legal Disclaimer

Note: Product cover images may vary from those shown